Navigation Links
Clarient Reports 2009 Third Quarter; Nine Month Results
Date:11/3/2009

ects of a going concern audit opinion on the Company's operations, the Company's ability to successfully transition its billing function in-house from a thirdparty vendor , the Company's ability to remediate the material weaknesses in the Company's internal control over financial reporting, the continuation of favorable third-party payor reimbursement for laboratory tests, the Company's ability to obtain additional financing on acceptable terms or at all, unanticipated expenses or liabilities or other adverse events affecting cash flow, uncertainty of success in identifying and developing new diagnostic tests or novel markers, the Company's ability to fund development of new diagnostic tests and novel markers and the amount of resources the Company determines to apply to novel marker development and commercialization, failure to obtain FDA clearance or approval for particular applications, the Company's ability to compete with other technologies and with emerging competitors in novel cancer diagnostics and dependence on third parties for collaboration in developing new tests, and risks detailed from time to time in the Company's SEC reports, including quarterly reports on Form 10-Q, reports on Form 8-K and annual reports on Form 10-K. Recent experience with respect to laboratory services, revenues and results of operations may not be indicative of future results for the reasons set forth above.

The Company does not assume any obligation to update any forward-looking statements or other information contained in this document.

Adjusted EBITDA Definition

"Adjusted EBITDA" is defined by the Company as income or loss from continuing operations before (i) interest expense, (ii) tax expense, (iii) depreciation and amortization expense and (iv) stock-based compensation expense. Adjusted EBITDA as defined by the Company may differ from non-GAAP measures used by other companies and is not a measurement under GAAP.
'/>"/>

SOURCE Clarient, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Clarient to Present at Noble Financials 5th Annual Equity Conference on Tuesday, June 9th
2. Clarient Completes Second Tranche of Private Placement of Convertible Preferred Stock With Oak Investment Partners
3. Clarient Granted Exclusive License to Commercialize Breast Cancer Biomarker by Indiana University Research and Technology Corporation
4. Clarient Reports Strong Revenue Increase for Fourth Quarter and Full-Year 2008
5. [video] Ronald Andrews, CEO of Clarient, Inc. Discusses Agreement With University of Pennsylvania School of Medicine on WallSt.nets 3-Minute Press Show
6. Clarient Names Raymond J. Land Senior Vice President and Chief Financial Officer
7. Jim Agnello to Resign as Clarient Chief Financial Officer
8. Clarient Announces Fourth Quarter and Year-End 2007 Financial Results
9. CombiMatrix and Clarient Collaborate to Market, Sell Novel Genomics-Based Test for Chronic Lymphotic Leukemia (CLL)
10. Clarient to Commercialize Novel Breast Cancer Profile
11. Clarient CEO Ron Andrews to Participate in OneMedPlace Emerging Healthcare Technologies Finance Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... New Orleans, LA (PRWEB) June 02, 2015 ... of custom gene synthesis to improve protein expression, announced ... The board includes six executives and entrepreneurs with a ... and software industries. , The team includes: , ... Startup Fund: , Roussel has a background in technology ...
(Date:6/1/2015)... South Korea , June 1, 2015 ... Cross Biotherapeutics Inc. (GCBT) kicked off construction today on ... Montreal Technoparc,s Saint-Laurent Campus. The CA$315 million project represents ... Canada in the biopharmaceutical industry, ... immunoglobulin (IVIG) and albumin manufacturing plant in ...
(Date:6/1/2015)... Inc. (TSX-V: BRM) ("Biorem" or "the Company") today announced results for ... first quarter financial statements and MD&A have been filed on SEDAR ... 31,(in CDN$,000 except per share data) , 2015 , ... profit , 1,531 , 329 Ebitda* , ... , (531) Basic earnings (loss) per share ...
(Date:6/1/2015)... 2015 Regis Technologies, Inc. is ... chiral stationary phases (CSPs) for analytical and preparative ... and presenting solutions for new clients, Regis implemented ... valuable addition to its core expertise in chiral ... can tackle projects for the scale clients need–from ...
Breaking Biology Technology:GenoCAD Announces New Board of Advisors, Improves Protein Expression Using Custom Gene Synthesis 2GenoCAD Announces New Board of Advisors, Improves Protein Expression Using Custom Gene Synthesis 3Green Cross Biotherapeutics Kicks Off Construction in Montreal 2Green Cross Biotherapeutics Kicks Off Construction in Montreal 3Biorem Reports Increased Revenues and Earnings for First Quarter 2Biorem Reports Increased Revenues and Earnings for First Quarter 3Regis Technologies Offers Chiral Chromatography Service 2Regis Technologies Offers Chiral Chromatography Service 3
... , , Alberta Centre ... health & medical seminar, , EDMONTON, Dec. 4 /PRNewswire/ ... how technologies like nanotechnology, biomaterials and microfluidics can play a ... help promote health and improve the quality, cost and outcomes ...
... , DALLAS, Dec. 3 ... Bulletin Board: ACCP), today provided an update on its European ... mucositis, a debilitating side effect of radiation treatment and chemotherapy. ... European countries, including the UK, Germany, Italy, Norway, Greece and ...
... , HOPKINTON, Mass., Dec. 3 Caliper Life Sciences, ... and services for drug discovery and life sciences research, today ... systems. Living Image software drives the more than 800 Caliper ... features advanced spectral unmixing tools to enhance fluorescent sensitivity and ...
Cached Biology Technology:Alberta companies delivering new products to the health & medical marketplace 2Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 2Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 3Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 4Caliper Life Sciences Launches Living Image(R) 4.0 Software 2
(Date:5/22/2015)... 22, 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... be ending its promotional pricing and making the Wocket generally ... Laurence Savin , Head of Marketing said, "We,ve extended the ... the end of May. To get your wocket at this ... open the store on June 1, you,ll receive a unique ...
(Date:5/21/2015)... The Sync Project™ , a global collaboration harnessing ... a collaborative partnership with Berklee,s Institute for Creative ... on original research, joint course development and an internship ... Sync Project and BerkleeICE are exploring the launch of ... academic year.  The course will focus ...
(Date:5/19/2015)... 2015 Fingerprint Cards (FPC) has received ... FPC1155 and FPC1035 from one if its module partners. Deliveries ... Q3 2015 and the sensors will be used by smartphone ... for 2015 hereby amount to 740 MSEK to date. In ... MSEK and a number of smaller orders not separately communicated ...
Breaking Biology News(10 mins):NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 2NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 3The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 2The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 3Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2
... early stages of cancer could one day result from new ... Universitys School of Medicine has just published a study on ... which can play a crucial part in the onset of ... by gradually becoming shorter they can tell cells when it ...
... beleaguered growers of popular cucurbit crops like cucumbers and ... (Lagenaria siceraria) appear to have resistance to Zucchini yellow ... includes pumpkins, squashes and other kinds of melons, including ... in other parts of world, and is a particular ...
... 2, 2007The Keck School of Medicine of the University of ... the Kenneth T. & Eileen L. Norris Foundation that will ... centers devoted to the study of epigenetics. The grant ... field that holds great promise in the treatment and prevention ...
Cached Biology News:Research points towards early cancer detection 2Battling virus disease of watermelon with bottlegourds 2$10 million gift to support cutting-edge epigenome center at USC 2$10 million gift to support cutting-edge epigenome center at USC 3
AM100 is an aqueous-based, permanent mounting media designed for use with alkaline phosphatase and immunoperoxidase stained tissue sections....
...
... Buffer, used in conjunction with eBioscience ... be used to fix and permeabilize ... of cytokines and other cytoplasmic and/or ... specially formulated for reducing non-specific staining ...
... ( Abpromise for all tested applications). ... conjugated to KLH derived from within residues ... amino acid sequence is proprietary)(Peptide available as ... Gene ID: 55693 ...
Biology Products: